Heparin-Induced Thrombocytopenia

ASH recognized three Choosing Wisely champions and three guideline implementation champions at this year’s ASH Annual Meeting and Exposition.

The FDA granted fast track designation to VLX-1005 for treatment of heparin-induced thrombocytopenia.

Gabriela S. Hobbs, MD, and Oluwatoyosi Adefunke Onwuemene, MD, MS, will participate in the American Society of Hematology-Harold Amos Medical Faculty Development Program.